1. Therapy Areas
  2. Other Disease Areas
  3. Asthma

ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder)

Enerzair® Breezhaler®

Inhaler Technique Video for Enerzair® Breezhaler®

1, 2, 3, Check, Inhaler Technique for Enerzair® Breezhaler®

Inhaler Technique Flyer for Enerzair® Breezhaler® Patients

Download Flyer

ie402247_enerzair_instructionsbookmark

ie402247_enerzair_instructionsbookmark

Rate this content: 
No votes yet
IE413067 | February 2024
Respiratory
Enerzair Breezhaler
Medicines
ENERZAIR® BREEZHALER® SPC
ATECTURA® BREEZHALER® SPC
Print
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.